) recently presented new data from the RAPID-PsA study and
RAPID-axSpA study on Cimzia. The data was presented at the
European League Against Rheumatism (EULAR) Congress.
According to the recent findings, active psoriatic arthritis
(PsA) and active axial spondyloarthritis (axSpA) patients treated
with Cimzia showed improvements in pain, fatigue and
health-related quality of life. Cimzia-treated PsA and axSpA
patients have shown better workplace and household productivity,
as well as more participation in social and daily activities as
compared to those being administered placebo.
Similar observations were seen in ankylosing spondylitis (AS)
and non-radiographic axSpA (nr-axSpA) patients treated with
Cimzia is currently approved for Crohn's disease and
rheumatoid arthritis. Cimzia sales increased 27% year over year
in the first quarter of 2013.
In Feb 2013, UCB filed with the US Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) for
two additional indications - PsA and axSpA. These regulatory
filings were based on the phase III RAPID-PsA and RAPID-axSpA
RAPID-PsA was a double-blind, placebo-controlled, phase III
study which showed improvements in the signs and symptoms of PsA
compared to placebo in adult patients with or without prior
anti-TNF (tumor necrosis factor) exposure.
RAPID-axSpA was a randomized, double-blind,
placebo-controlled, phase III study which showed that both dosing
regimens of Cimzia reduced the signs and symptoms of axSpA as
compared to placebo.
Currently, the psoriatic arthritis market has drugs like
) Humira and
Johnson & Johnson
) Simponi among others.
UCB carries a Zacks Rank #3 (Hold). However,
) looks more attractive with a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.